Merck KGaA (XSWX:MER) Asset Impairment Charge: CHF0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MER Merck KGaA XSWX:MER
84 GF Score
Price CHF130.50
GF Value CHF132.45
! 10 Warning Signs
View Full Analysis

What is Merck KGaA Asset Impairment Charge?

Merck KGaA XSWX:MER 84 Asset Impairment Charge is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:MER with a GF Score™ of 84/100 and a GF Value™ of CHF132.45. The stock has 10 warning signs investors should review.

Merck KGaA's Asset Impairment Charge for the three months ended in Mar. 2026 was CHF0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 was CHF0 Mil.

Merck KGaA Asset Impairment Charge Related Terms

Merck KGaA Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Asset Impairment Charge Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Merck KGaA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:MER
84GF Score
Merck KGaA XSWX:MER
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

What does a Asset Impairment Charge of CHF0 Mil mean?
Merck KGaA (XSWX:MER) has a Asset Impairment Charge of CHF0 Mil as of Mar. 2026.
Is Merck KGaA's Asset Impairment Charge too high?
Merck KGaA's current Asset Impairment Charge is CHF0 Mil. Overall, Merck KGaA has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Asset Impairment Charge compare to ZTS and UTHR?
Merck KGaA's Asset Impairment Charge of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Drug Manufacturers company?
A good Asset Impairment Charge depends on the Drug Manufacturers industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Merck KGaA's current Asset Impairment Charge is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Merck KGaA (XSWX:MER) has a current Asset Impairment Charge of CHF0 Mil. The stock's GF Value™ is CHF132.45, compared to a current price of CHF130.50 — trading 1.5% below its estimated fair value. The current Asset Impairment Charge is CHF0 Mil. Merck KGaA's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Merck KGaA (XSWX:MER), the current Asset Impairment Charge is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (XSWX:MER) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of CHF130.50 is trading 1.5% below its estimated GF Value™ of CHF132.45.

Key valuation signals for XSWX:MER:

  • Asset Impairment Charge: CHF0 Mil
  • GF Value™: CHF132.45 vs. price of CHF130.50 (1.5% below fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the XSWX:MER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
84GF Score

Get the complete analysis for XSWX:MER

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF130.50
Price
CHF132.45
GF Value